Skip to main content
Top
Published in: Endocrine 1/2013

01-08-2013 | Original Article

Different levels of various glucocorticoid-regulated genes in corticotroph adenomas

Authors: Johan Arild Evang, Jens Bollerslev, Olivera Casar-Borota, Tove Lekva, Jon Ramm-Pettersen, Jens Petter Berg

Published in: Endocrine | Issue 1/2013

Login to get access

Abstract

Recently, correlations between corticotroph tumor dedifferentiation and both E-cadherin immunostaining and reduced mRNA expression of the E-cadherin gene (CDH1) have been demonstrated. The purpose of this study was to explore whether tumor dedifferentiation correlated with glucocorticoid resistance and whether the resistance was associated with both positively and negatively regulated genes. Tumor material from 20 patients with verified Cushing’s disease or Nelson’s syndrome operated on at Rikshospitalet, Oslo. Reverse transcription polymerase chain reaction analysis of genes such as E-cadherin (CDH1), proopiomelanocortin (POMC), glucocorticoid-induced leucine zipper (GILZ), and thioredoxin-interacting protein (TXNIP) was performed. The correlations between the expression of the GILZ, TXNIP, and POMC genes in different stages of corticotroph adenomas, the E-cadherin mRNA expression and staining pattern, and the preoperative 24-h cortisol excretion were examined. The GILZ and TXNIP expression levels were positively correlated to the CDH1 expression and were highest in microadenomas and in tumors with a high membranous E-cadherin reactivity. In contrast, the POMC expression was not significantly different between the groups. This divergence between the genes that were positively and negatively regulated by glucocorticoids could not be supported by other gene expression analyses. No correlations to urinary cortisol were found. The expression of the glucocorticoid-responsive genes POMC, GILZ, and TXNIP in corticotroph adenomas showed a remarkable variation. The pattern and variability of glucocorticoid resistance in corticotroph adenomas seem to correlate with a loss of the epithelial phenotype associated with corticotroph tumor dedifferentiation.
Literature
1.
go back to reference V. Hook, L. Funkelstein, T. Toneff, C. Mosier, S.R. Hwang, Human pituitary contains dual cathepsin L and prohormone convertase processing pathway components involved in converting POMC into the peptide hormones ACTH, alpha-MSH, and beta-endorphin. Endocrine 35, 429–437 (2009)PubMedCrossRef V. Hook, L. Funkelstein, T. Toneff, C. Mosier, S.R. Hwang, Human pituitary contains dual cathepsin L and prohormone convertase processing pathway components involved in converting POMC into the peptide hormones ACTH, alpha-MSH, and beta-endorphin. Endocrine 35, 429–437 (2009)PubMedCrossRef
2.
go back to reference L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart, V.M. Montori, The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 93, 1526–1540 (2008)PubMedCrossRef L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart, V.M. Montori, The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 93, 1526–1540 (2008)PubMedCrossRef
3.
go back to reference N.A. Huizenga, P. de Lange, J.W. Koper, R.N. Clayton, W.E. Farrell, A.J. van der Lely, A.O. Brinkmann, F.H. de Jong, S.W. Lamberts, Human adrenocorticotropin-secreting pituitary adenomas show frequent loss of heterozygosity at the glucocorticoid receptor gene locus. J. Clin. Endocrinol. Metab. 83, 917–921 (1998)PubMedCrossRef N.A. Huizenga, P. de Lange, J.W. Koper, R.N. Clayton, W.E. Farrell, A.J. van der Lely, A.O. Brinkmann, F.H. de Jong, S.W. Lamberts, Human adrenocorticotropin-secreting pituitary adenomas show frequent loss of heterozygosity at the glucocorticoid receptor gene locus. J. Clin. Endocrinol. Metab. 83, 917–921 (1998)PubMedCrossRef
4.
go back to reference M. Korbonits, I. Bujalska, M. Shimojo, J. Nobes, S. Jordan, A.B. Grossman, P.M. Stewart, Expression of 11 beta-hydroxysteroid dehydrogenase isoenzymes in the human pituitary: induction of the type 2 enzyme in corticotropinomas and other pituitary tumors. J. Clin. Endocrinol. Metab. 86, 2728–2733 (2001)PubMedCrossRef M. Korbonits, I. Bujalska, M. Shimojo, J. Nobes, S. Jordan, A.B. Grossman, P.M. Stewart, Expression of 11 beta-hydroxysteroid dehydrogenase isoenzymes in the human pituitary: induction of the type 2 enzyme in corticotropinomas and other pituitary tumors. J. Clin. Endocrinol. Metab. 86, 2728–2733 (2001)PubMedCrossRef
5.
go back to reference M. Karl, S.W. Lamberts, J.W. Koper, D.A. Katz, N.E. Huizenga, T. Kino, B.R. Haddad, M.R. Hughes, G.P. Chrousos, Cushing’s disease preceded by generalized glucocorticoid resistance: clinical consequences of a novel, dominant-negative glucocorticoid receptor mutation. Proc. Assoc. Am. Physicians 108, 296–307 (1996)PubMed M. Karl, S.W. Lamberts, J.W. Koper, D.A. Katz, N.E. Huizenga, T. Kino, B.R. Haddad, M.R. Hughes, G.P. Chrousos, Cushing’s disease preceded by generalized glucocorticoid resistance: clinical consequences of a novel, dominant-negative glucocorticoid receptor mutation. Proc. Assoc. Am. Physicians 108, 296–307 (1996)PubMed
6.
go back to reference S.R. Antonini, A.C. Latronico, L.L. Elias, A. Cukiert, H.R. Machado, B. Liberman, B.B. Mendonca, A.C. Moreira, M. Castro, Glucocorticoid receptor gene polymorphisms in ACTH-secreting pituitary tumours. Clin. Endocrinol. (Oxf.) 57, 657–662 (2002)CrossRef S.R. Antonini, A.C. Latronico, L.L. Elias, A. Cukiert, H.R. Machado, B. Liberman, B.B. Mendonca, A.C. Moreira, M. Castro, Glucocorticoid receptor gene polymorphisms in ACTH-secreting pituitary tumours. Clin. Endocrinol. (Oxf.) 57, 657–662 (2002)CrossRef
7.
go back to reference D.G. Morris, B. Kola, N. Borboli, G.A. Kaltsas, M. Gueorguiev, A.M. McNicol, R. Ferrier, T.H. Jones, S. Baldeweg, M. Powell, S. Czirjak, Z. Hanzely, J.O. Johansson, M. Korbonits, A.B. Grossman, Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas. J. Clin. Endocrinol. Metab. 88, 6080–6087 (2003)PubMedCrossRef D.G. Morris, B. Kola, N. Borboli, G.A. Kaltsas, M. Gueorguiev, A.M. McNicol, R. Ferrier, T.H. Jones, S. Baldeweg, M. Powell, S. Czirjak, Z. Hanzely, J.O. Johansson, M. Korbonits, A.B. Grossman, Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas. J. Clin. Endocrinol. Metab. 88, 6080–6087 (2003)PubMedCrossRef
8.
go back to reference A. Lania, G. Mantovani, A. Spada, Genetics of pituitary tumors: focus on G-protein mutations. Exp. Biol. Med. (Maywood) 228, 1004–1017 (2003) A. Lania, G. Mantovani, A. Spada, Genetics of pituitary tumors: focus on G-protein mutations. Exp. Biol. Med. (Maywood) 228, 1004–1017 (2003)
9.
go back to reference S. Bilodeau, S. Vallette-Kasic, Y. Gauthier, D. Figarella-Branger, T. Brue, F. Berthelet, A. Lacroix, D. Batista, C. Stratakis, J. Hanson, B. Meij, J. Drouin, Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev. 20, 2871–2886 (2006)PubMedCrossRef S. Bilodeau, S. Vallette-Kasic, Y. Gauthier, D. Figarella-Branger, T. Brue, F. Berthelet, A. Lacroix, D. Batista, C. Stratakis, J. Hanson, B. Meij, J. Drouin, Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev. 20, 2871–2886 (2006)PubMedCrossRef
10.
go back to reference C.M. Bamberger, A.M. Bamberger, M. de Castro, G.P. Chrousos, Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J. Clin. Invest. 95, 2435–2441 (1995)PubMedCrossRef C.M. Bamberger, A.M. Bamberger, M. de Castro, G.P. Chrousos, Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J. Clin. Invest. 95, 2435–2441 (1995)PubMedCrossRef
11.
go back to reference T. Kino, Y.A. Su, G.P. Chrousos, Human glucocorticoid receptor isoform beta: recent understanding of its potential implications in physiology and pathophysiology. Cell. Mol. Life Sci. 66, 3435–3448 (2009)PubMedCrossRef T. Kino, Y.A. Su, G.P. Chrousos, Human glucocorticoid receptor isoform beta: recent understanding of its potential implications in physiology and pathophysiology. Cell. Mol. Life Sci. 66, 3435–3448 (2009)PubMedCrossRef
12.
go back to reference T. Kino, D.E. Hurt, T. Ichijo, N. Nader, G.P. Chrousos, Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. Sci. Signal. 3, ra8 (2010)PubMedCrossRef T. Kino, D.E. Hurt, T. Ichijo, N. Nader, G.P. Chrousos, Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. Sci. Signal. 3, ra8 (2010)PubMedCrossRef
13.
go back to reference P.D. Reynolds, Y. Ruan, D.F. Smith, J.G. Scammell, Glucocorticoid resistance in the squirrel monkey is associated with overexpression of the immunophilin FKBP51. J. Clin. Endocrinol. Metab. 84, 663–669 (1999)PubMedCrossRef P.D. Reynolds, Y. Ruan, D.F. Smith, J.G. Scammell, Glucocorticoid resistance in the squirrel monkey is associated with overexpression of the immunophilin FKBP51. J. Clin. Endocrinol. Metab. 84, 663–669 (1999)PubMedCrossRef
14.
go back to reference W.B. Denny, V. Prapapanich, D.F. Smith, J.G. Scammell, Structure–function analysis of squirrel monkey FK506-binding protein 51, a potent inhibitor of glucocorticoid receptor activity. Endocrinology 146, 3194–3201 (2005)PubMedCrossRef W.B. Denny, V. Prapapanich, D.F. Smith, J.G. Scammell, Structure–function analysis of squirrel monkey FK506-binding protein 51, a potent inhibitor of glucocorticoid receptor activity. Endocrinology 146, 3194–3201 (2005)PubMedCrossRef
15.
go back to reference Z.R. Qian, T. Sano, K. Yoshimoto, S.L. Asa, S. Yamada, N. Mizusawa, E. Kudo, Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod. Pathol. 20, 1269–1277 (2007)PubMedCrossRef Z.R. Qian, T. Sano, K. Yoshimoto, S.L. Asa, S. Yamada, N. Mizusawa, E. Kudo, Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod. Pathol. 20, 1269–1277 (2007)PubMedCrossRef
16.
go back to reference F. Salehi, A. Agur, B.W. Scheithauer, K. Kovacs, R.V. Lloyd, M. Cusimano, Ki-67 in pituitary neoplasms: a review—part I. Neurosurgery 65, 429–437 (2009)PubMedCrossRef F. Salehi, A. Agur, B.W. Scheithauer, K. Kovacs, R.V. Lloyd, M. Cusimano, Ki-67 in pituitary neoplasms: a review—part I. Neurosurgery 65, 429–437 (2009)PubMedCrossRef
17.
go back to reference J.A. Evang, J.P. Berg, O. Casar-Borota, T. Lekva, M.K. Kringen, J. Ramm-Pettersen, J. Bollerslev, Reduced levels of E-cadherin correlate with progression of corticotroph pituitary tumours. Clin. Endocrinol. (Oxf.) 75, 811–818 (2011)CrossRef J.A. Evang, J.P. Berg, O. Casar-Borota, T. Lekva, M.K. Kringen, J. Ramm-Pettersen, J. Bollerslev, Reduced levels of E-cadherin correlate with progression of corticotroph pituitary tumours. Clin. Endocrinol. (Oxf.) 75, 811–818 (2011)CrossRef
18.
go back to reference P. Selvais, J. Donckier, M. Buysschaert, D. Maiter, Cushing’s disease: a comparison of pituitary corticotroph microadenomas and macroadenomas. Eur. J. Endocrinol. 138, 153–159 (1998)PubMedCrossRef P. Selvais, J. Donckier, M. Buysschaert, D. Maiter, Cushing’s disease: a comparison of pituitary corticotroph microadenomas and macroadenomas. Eur. J. Endocrinol. 138, 153–159 (1998)PubMedCrossRef
19.
go back to reference L. Katznelson, J.S. Bogan, J.R. Trob, D.A. Schoenfeld, E.T. Hedley-Whyte, D.W. Hsu, N.T. Zervas, B. Swearingen, M. Sleeper, A. Klibanski, Biochemical assessment of Cushing’s disease in patients with corticotroph macroadenomas. J. Clin. Endocrinol. Metab. 83, 1619–1623 (1998)PubMedCrossRef L. Katznelson, J.S. Bogan, J.R. Trob, D.A. Schoenfeld, E.T. Hedley-Whyte, D.W. Hsu, N.T. Zervas, B. Swearingen, M. Sleeper, A. Klibanski, Biochemical assessment of Cushing’s disease in patients with corticotroph macroadenomas. J. Clin. Endocrinol. Metab. 83, 1619–1623 (1998)PubMedCrossRef
20.
go back to reference Y.S. Woo, A.M. Isidori, W.Z. Wat, G.A. Kaltsas, F. Afshar, I. Sabin, P.J. Jenkins, J.P. Monson, G.M. Besser, A.B. Grossman, Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J. Clin. Endocrinol. Metab. 90, 4963–4969 (2005)PubMedCrossRef Y.S. Woo, A.M. Isidori, W.Z. Wat, G.A. Kaltsas, F. Afshar, I. Sabin, P.J. Jenkins, J.P. Monson, G.M. Besser, A.B. Grossman, Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J. Clin. Endocrinol. Metab. 90, 4963–4969 (2005)PubMedCrossRef
21.
go back to reference M. Losa, R.L. Barzaghi, P. Mortini, A. Franzin, F. Mangili, M.R. Terreni, M. Giovanelli, Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors : comparison between micro- and macroadenomas. Am. J. Pathol. 156, 245–251 (2000)PubMedCrossRef M. Losa, R.L. Barzaghi, P. Mortini, A. Franzin, F. Mangili, M.R. Terreni, M. Giovanelli, Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors : comparison between micro- and macroadenomas. Am. J. Pathol. 156, 245–251 (2000)PubMedCrossRef
22.
go back to reference T.M. Barber, E. Adams, O. Ansorge, J.V. Byrne, N. Karavitaki, J.A. Wass, Nelson’s syndrome. Eur. J. Endocrinol. 163, 495–507 (2010)PubMedCrossRef T.M. Barber, E. Adams, O. Ansorge, J.V. Byrne, N. Karavitaki, J.A. Wass, Nelson’s syndrome. Eur. J. Endocrinol. 163, 495–507 (2010)PubMedCrossRef
23.
go back to reference F. D’Adamio, O. Zollo, R. Moraca, E. Ayroldi, S. Bruscoli, A. Bartoli, L. Cannarile, G. Migliorati, C. Riccardi, A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity 7, 803–812 (1997)PubMedCrossRef F. D’Adamio, O. Zollo, R. Moraca, E. Ayroldi, S. Bruscoli, A. Bartoli, L. Cannarile, G. Migliorati, C. Riccardi, A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity 7, 803–812 (1997)PubMedCrossRef
24.
go back to reference Z. Wang, Y.P. Rong, M.H. Malone, M.C. Davis, F. Zhong, C.W. Distelhorst, Thioredoxin-interacting protein (TXNIP) is a glucocorticoid-regulated primary response gene involved in mediating glucocorticoid-induced apoptosis. Oncogene 25, 1903–1913 (2006)PubMedCrossRef Z. Wang, Y.P. Rong, M.H. Malone, M.C. Davis, F. Zhong, C.W. Distelhorst, Thioredoxin-interacting protein (TXNIP) is a glucocorticoid-regulated primary response gene involved in mediating glucocorticoid-induced apoptosis. Oncogene 25, 1903–1913 (2006)PubMedCrossRef
25.
go back to reference W.J. Tissing, M.L. Den Boer, J.P. Meijerink, R.X. Menezes, S. Swagemakers, P.J. van der Spek, S.E. Sallan, S.A. Armstrong, R. Pieters, Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. Blood 109, 3929–3935 (2007)PubMedCrossRef W.J. Tissing, M.L. Den Boer, J.P. Meijerink, R.X. Menezes, S. Swagemakers, P.J. van der Spek, S.E. Sallan, S.A. Armstrong, R. Pieters, Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. Blood 109, 3929–3935 (2007)PubMedCrossRef
26.
go back to reference T. Lekva, J. Bollerslev, C. Kristo, O.K. Olstad, T. Ueland, R. Jemtland, The glucocorticoid-induced leucine zipper gene (GILZ) expression decreases after successful treatment of patients with endogenous Cushing’s syndrome and may play a role in glucocorticoid-induced osteoporosis. J. Clin. Endocrinol. Metab. 95, 246–255 (2010)PubMedCrossRef T. Lekva, J. Bollerslev, C. Kristo, O.K. Olstad, T. Ueland, R. Jemtland, The glucocorticoid-induced leucine zipper gene (GILZ) expression decreases after successful treatment of patients with endogenous Cushing’s syndrome and may play a role in glucocorticoid-induced osteoporosis. J. Clin. Endocrinol. Metab. 95, 246–255 (2010)PubMedCrossRef
27.
go back to reference T. Lekva, T. Ueland, H. Boyum, J.A. Evang, K. Godang, J. Bollerslev, TXNIP is highly regulated in bone biopsies from patients with endogenous Cushing’s syndrome and related to bone turnover. Eur. J. Endocrinol. 166(6), 1039–1048 (2012)PubMedCrossRef T. Lekva, T. Ueland, H. Boyum, J.A. Evang, K. Godang, J. Bollerslev, TXNIP is highly regulated in bone biopsies from patients with endogenous Cushing’s syndrome and related to bone turnover. Eur. J. Endocrinol. 166(6), 1039–1048 (2012)PubMedCrossRef
28.
go back to reference A.Y. So, S.B. Cooper, B.J. Feldman, M. Manuchehri, K.R. Yamamoto, Conservation analysis predicts in vivo occupancy of glucocorticoid receptor-binding sequences at glucocorticoid-induced genes. Proc. Natl. Acad. Sci. USA. 105, 5745–5749 (2008)PubMedCrossRef A.Y. So, S.B. Cooper, B.J. Feldman, M. Manuchehri, K.R. Yamamoto, Conservation analysis predicts in vivo occupancy of glucocorticoid receptor-binding sequences at glucocorticoid-induced genes. Proc. Natl. Acad. Sci. USA. 105, 5745–5749 (2008)PubMedCrossRef
29.
go back to reference S.L. Fougner, J. Bollerslev, F. Latif, J.K. Hald, T. Lund, J. Ramm-Pettersen, J.P. Berg, Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. J. Clin. Endocrinol. Metab. 93, 1211–1216 (2008)PubMedCrossRef S.L. Fougner, J. Bollerslev, F. Latif, J.K. Hald, T. Lund, J. Ramm-Pettersen, J.P. Berg, Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. J. Clin. Endocrinol. Metab. 93, 1211–1216 (2008)PubMedCrossRef
30.
go back to reference G. Raverot, A. Wierinckx, E. Jouanneau, C. Auger, F. Borson-Chazot, J. Lachuer, M. Pugeat, J. Trouillas, Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing’s disease. Eur. J. Endocrinol. 163, 35–43 (2010)PubMedCrossRef G. Raverot, A. Wierinckx, E. Jouanneau, C. Auger, F. Borson-Chazot, J. Lachuer, M. Pugeat, J. Trouillas, Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing’s disease. Eur. J. Endocrinol. 163, 35–43 (2010)PubMedCrossRef
31.
go back to reference U. M, L. Shen, T. Oshida, J. Miyauchi, M. Yamada, T. Miyashita, Identification of novel direct transcriptional targets of glucocorticoid receptor. Leukemia 18, 1850–1856 (2004)CrossRef U. M, L. Shen, T. Oshida, J. Miyauchi, M. Yamada, T. Miyashita, Identification of novel direct transcriptional targets of glucocorticoid receptor. Leukemia 18, 1850–1856 (2004)CrossRef
32.
go back to reference S.L. Fougner, T. Lekva, O.C. Borota, J.K. Hald, J. Bollerslev, J.P. Berg, The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J. Clin. Endocrinol. Metab. 95, 2334–2342 (2010)PubMedCrossRef S.L. Fougner, T. Lekva, O.C. Borota, J.K. Hald, J. Bollerslev, J.P. Berg, The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J. Clin. Endocrinol. Metab. 95, 2334–2342 (2010)PubMedCrossRef
33.
go back to reference M.S. Elston, A.J. Gill, J.V. Conaglen, A. Clarkson, R.J. Cook, N.S. Little, B.G. Robinson, R.J. Clifton-Bligh, K.L. McDonald, Nuclear accumulation of E-cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas. J. Clin. Endocrinol. Metab. 94, 1436–1442 (2009)PubMedCrossRef M.S. Elston, A.J. Gill, J.V. Conaglen, A. Clarkson, R.J. Cook, N.S. Little, B.G. Robinson, R.J. Clifton-Bligh, K.L. McDonald, Nuclear accumulation of E-cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas. J. Clin. Endocrinol. Metab. 94, 1436–1442 (2009)PubMedCrossRef
34.
go back to reference B. Xu, T. Sano, K. Yoshimoto, S. Yamada, Downregulation of E-cadherin and its undercoat proteins in pituitary growth hormone cell adenomas with prominent fibrous bodies. Endocr. Pathol. 13, 341–351 (2002)PubMedCrossRef B. Xu, T. Sano, K. Yoshimoto, S. Yamada, Downregulation of E-cadherin and its undercoat proteins in pituitary growth hormone cell adenomas with prominent fibrous bodies. Endocr. Pathol. 13, 341–351 (2002)PubMedCrossRef
35.
go back to reference H. Kawamoto, T. Mizoue, K. Arita, A. Tominaga, K. Eguchi, K. Kurisu, Expression of epithelial cadherin and cavernous sinus invasion in human pituitary adenomas. J. Neurooncol. 34, 105–109 (1997)PubMedCrossRef H. Kawamoto, T. Mizoue, K. Arita, A. Tominaga, K. Eguchi, K. Kurisu, Expression of epithelial cadherin and cavernous sinus invasion in human pituitary adenomas. J. Neurooncol. 34, 105–109 (1997)PubMedCrossRef
36.
go back to reference S. Wolfsberger, J. Wunderer, I. Zachenhofer, T. Czech, H.G. Bocher-Schwarz, J. Hainfellner, E. Knosp, Expression of cell proliferation markers in pituitary adenomas—correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha. Acta Neurochir. 146, 831–839 (2004)PubMed S. Wolfsberger, J. Wunderer, I. Zachenhofer, T. Czech, H.G. Bocher-Schwarz, J. Hainfellner, E. Knosp, Expression of cell proliferation markers in pituitary adenomas—correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha. Acta Neurochir. 146, 831–839 (2004)PubMed
37.
go back to reference H.E. Turner, Z. Nagy, K.C. Gatter, M.M. Esiri, J.A. Wass, A.L. Harris, Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour. Br. J. Cancer 82, 1441–1445 (2000)PubMedCrossRef H.E. Turner, Z. Nagy, K.C. Gatter, M.M. Esiri, J.A. Wass, A.L. Harris, Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour. Br. J. Cancer 82, 1441–1445 (2000)PubMedCrossRef
38.
go back to reference F. Salehi, A. Agur, B.W. Scheithauer, K. Kovacs, R.V. Lloyd, M. Cusimano, Biomarkers of pituitary neoplasms: a review (Part II). Neurosurgery 67, 1790–1798 (2010)PubMedCrossRef F. Salehi, A. Agur, B.W. Scheithauer, K. Kovacs, R.V. Lloyd, M. Cusimano, Biomarkers of pituitary neoplasms: a review (Part II). Neurosurgery 67, 1790–1798 (2010)PubMedCrossRef
Metadata
Title
Different levels of various glucocorticoid-regulated genes in corticotroph adenomas
Authors
Johan Arild Evang
Jens Bollerslev
Olivera Casar-Borota
Tove Lekva
Jon Ramm-Pettersen
Jens Petter Berg
Publication date
01-08-2013
Publisher
Springer US
Published in
Endocrine / Issue 1/2013
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9871-0

Other articles of this Issue 1/2013

Endocrine 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.